{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:08:43Z","timestamp":1789470523085,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013607","name":"American College of Clinical Pharmacy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.josat.2023.209237","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T18:38:51Z","timestamp":1701801531000},"page":"209237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective"],"prefix":"10.1016","volume":"160","author":[{"given":"Sun A.","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie H.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Gastala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Touchette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Stranges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.josat.2023.209237_bb0010","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jval.2020.03.015","article-title":"Economic evaluation of interventions to address opioid misuse: A systematic review of methods used in simulation modeling studies","volume":"23","author":"Barbosa","year":"2020","journal-title":"Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research"},{"issue":"6","key":"10.1016\/j.josat.2023.209237_bb0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.ADM.0000435321.39251.d7","article-title":"Safe methadone induction and stabilization: Report of an expert panel","volume":"7","author":"Baxter","year":"2013","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2023.209237_bb0020","series-title":"Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on drug use and health","author":"Bose","year":"2017"},{"key":"10.1016\/j.josat.2023.209237_bb0025","series-title":"Treating opioid use disorder as a chronic condition: A practice manual for family physicians","author":"Bravata","year":"2021"},{"key":"10.1016\/j.josat.2023.209237_bb0030","series-title":"Table 2.4.4. Price indexes for personal consumption expenditures by type of product","author":"Bureau of Economic Analysis","year":"2021"},{"issue":"12","key":"10.1016\/j.josat.2023.209237_bb0035","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/add.15959","article-title":"Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: A retrospective cohort study","volume":"117","author":"Burns","year":"2022","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.josat.2023.209237_bb0040","article-title":"Wide-ranging online data for epidemiologic research (WONDER)","author":"Centers for Disease Control and Prevention","year":"2023","journal-title":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.josat.2023.209237_bb0050","article-title":"CY 2021 PFS final rule OTP payment rates","author":"Centers for Medicare & Medicaid Services","year":"2021","journal-title":"Centers for Medicare & Medicaid Services."},{"key":"10.1016\/j.josat.2023.209237_bb0055","article-title":"Physician fee schedule","author":"Centers for Medicare & Medicaid Services","year":"2021","journal-title":"Centers for Medicare & Medicaid Services."},{"key":"10.1016\/j.josat.2023.209237_bb0045","series-title":"Office-based substance use disorder (SUD) treatment billing","author":"Centers for Medicare & Medicaid Services","year":"2023"},{"issue":"1","key":"10.1016\/j.josat.2023.209237_bb0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13722-017-0071-3","article-title":"A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence","volume":"12","author":"Chetty","year":"2017","journal-title":"Addiction Science & Clinical Practice"},{"issue":"3","key":"10.1016\/j.josat.2023.209237_bb0065","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/10550490600626606","article-title":"Buprenorphine treatment: A three-year prospective study in opioid-addicted patients of a public out-patient addiction center in Milan","volume":"15","author":"Cozzolino","year":"2006","journal-title":"The American Journal on Addictions"},{"issue":"2","key":"10.1016\/j.josat.2023.209237_bb0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000193","article-title":"A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction","volume":"10","author":"Dugosh","year":"2016","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.josat.2023.209237_bb0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/1475-6773.12612","article-title":"Adjusting health expenditures for inflation: A review of measures for health services research in the United States","volume":"53","author":"Dunn","year":"2018","journal-title":"Health Services Research"},{"key":"10.1016\/j.josat.2023.209237_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108350","article-title":"The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017","volume":"218","author":"Florence","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"10","key":"10.1016\/j.josat.2023.209237_bb0085","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.josat.2023.209237_bb0090","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/hec.618","article-title":"Discounting for health effects in cost-benefit and cost-effectiveness analysis","volume":"10","author":"Gravelle","year":"2001","journal-title":"Health Economics"},{"issue":"4","key":"10.1016\/j.josat.2023.209237_bb0095","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.josat.2023.209237_bb0100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial: Treatment retention on buprenorphine\/methadone","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2023.209237_bb0105","author":"INDIVIOR"},{"issue":"10","key":"10.1016\/j.josat.2023.209237_bb0110","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/pme.12183","article-title":"The economic burden of opioid-related poisoning in the United States","volume":"14","author":"Inocencio","year":"2013","journal-title":"Pain Medicine (Malden, Mass.)"},{"key":"10.1016\/j.josat.2023.209237_bb0115","author":"IQVIA"},{"issue":"7","key":"10.1016\/j.josat.2023.209237_bb0120","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: A systematic review: Review of XR-NTX for OUD","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.josat.2023.209237_bb0125","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/jamapsychiatry.2023.0310","article-title":"Association of receipt of opioid use disorder\u2013related telehealth services and medications for opioid use disorder with fatal drug overdoses among medicare beneficiaries before and during the COVID-19 pandemic","volume":"80","author":"Jones","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.josat.2023.209237_bb0130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/15360288.2015.1135847","article-title":"Office-based buprenorphine versus clinic-based methadone: A cost-effectiveness analysis","volume":"30","author":"King","year":"2016","journal-title":"Journal of Pain & Palliative Care Pharmacotherapy"},{"issue":"15","key":"10.1016\/j.josat.2023.209237_bb0135","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajhp\/zxz105","article-title":"Medications for management of opioid use disorder","volume":"76","author":"Koehl","year":"2019","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1016\/j.josat.2023.209237_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019\u2033","volume":"110","author":"Krawczyk","year":"2022","journal-title":"International Journal of Drug Policy"},{"issue":"3","key":"10.1016\/j.josat.2023.209237_bb0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"10118","key":"10.1016\/j.josat.2023.209237_bb0150","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.josat.2023.209237_bb0155","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","article-title":"Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial","volume":"93","author":"Ling","year":"1998","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.josat.2023.209237_bb0160","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/ADM.0000000000000517","article-title":"Patient-centered outcomes in participants of a buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, multicenter, phase 3 study","volume":"13","author":"Ling","year":"2019","journal-title":"Journal of Addiction Medicine"},{"issue":"11","key":"10.1016\/j.josat.2023.209237_bb0170","first-page":"1241","article-title":"Prescription opioid abuse: What is the real problem and how do we fix it?","volume":"57","author":"Lynch","year":"2011","journal-title":"Canadian family physician Medecin de famille canadien"},{"key":"10.1016\/j.josat.2023.209237_bb0175","article-title":"How do the hospital prices paid by Medicare advantage plans and commercial plans compare with Medicare fee-for-service prices? INQUIRY","volume":"55","author":"Maeda","year":"2018","journal-title":"The Journal of Health Care Organization, Provision, and Financing"},{"key":"10.1016\/j.josat.2023.209237_bb0180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jsat.2018.03.001","article-title":"Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review","volume":"89","author":"Maglione","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209237_bb0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jsat.2018.03.001","article-title":"Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review","volume":"89","author":"Maglione","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209237_bb0190","article-title":"How differences in medicaid, medicare, and commercial health insurance payment rates impact access, health equity, and cost","author":"Mann","year":"2022","journal-title":"The Commonwealth Fund."},{"issue":"4","key":"10.1016\/j.josat.2023.209237_bb0195","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/ajad.13018","article-title":"Case series: Rapid induction onto long acting buprenorphine injection for high potency synthetic opioid users","volume":"29","author":"Mariani","year":"2020","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.josat.2023.209237_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002209.pub2","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.josat.2023.209237_bb0205","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"3","author":"Mattick","year":"2004","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.josat.2023.209237_bb0005","doi-asserted-by":"crossref","unstructured":"American Society of Addiction Medicine (2020). The ASAM National Practice Guideline for the treatment of opioid use disorder \u2013 2020 focused update. Journal of Addiction Medicine, 14(2S Suppl 1), 1\u201391. https:\/\/doi.org\/10.1097\/ADM.0000000000000633.","DOI":"10.1097\/ADM.0000000000000633"},{"key":"10.1016\/j.josat.2023.209237_bb0210","unstructured":"Merative Micromedex. (2021). MICROMEDEX: Redbook. Merative Micromedex. www.micromedexsolutions.com."},{"key":"10.1016\/j.josat.2023.209237_bb0215","series-title":"Cochrane database of systematic reviews","article-title":"Oral naltrexone maintenance treatment for opioid dependence","author":"Minozzi","year":"2011"},{"issue":"1","key":"10.1016\/j.josat.2023.209237_bb0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","article-title":"Medication treatment for opioid use disorders in substance use treatment facilities","volume":"38","author":"Mojtabai","year":"2019","journal-title":"Health Affairs"},{"key":"10.1016\/j.josat.2023.209237_bb0225","first-page":"1","article-title":"Psychosocial supports in medication-assisted treatment: Recent evidence and current practice","author":"Moran","year":"2019","journal-title":"Office of the Assistant Secretary for Planning and Evaluation."},{"key":"10.1016\/j.josat.2023.209237_bb0230","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209237_bb0235","series-title":"Medications for Opioid Use Disorder Save Lives","article-title":"Barriers to broader use of medications to treat opioid use disorder","author":"National Academies of Sciences, E., Division, H. and M., Policy, B. on H. S., Disorder, C. on M.-A. T. for O. U","year":"2019"},{"key":"10.1016\/j.josat.2023.209237_bb0240","series-title":"CADTH Issues in Emerging Health Technologies","article-title":"Injectable extended-release naltrexone to treat opioid use disorder","author":"Ndegwa","year":"2016"},{"issue":"11","key":"10.1016\/j.josat.2023.209237_bb0245","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1016\/j.addbeh.2013.07.007","article-title":"Primary care patient characteristics associated with completion of 6-month buprenorphine treatment","volume":"38","author":"Neumann","year":"2013","journal-title":"Addictive Behaviors"},{"issue":"7","key":"10.1016\/j.josat.2023.209237_bb0250","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jval.2020.12.023","article-title":"Economic evaluations of pharmacologic treatment for opioid use disorder: A systematic literature review","volume":"24","author":"Onuoha","year":"2021","journal-title":"Value in Health"},{"issue":"11","key":"10.1016\/j.josat.2023.209237_bb0255","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.3833","article-title":"Assessment of state and Federal Health Policies for opioid use disorder treatment during the COVID-19 pandemic and beyond","volume":"2","author":"Pessar","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"1","key":"10.1016\/j.josat.2023.209237_bb0260","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0376-8716(00)00163-0","article-title":"Double-blind randomized trial of buprenorphine and methadone in opiate dependence","volume":"62","author":"Petitjean","year":"2001","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.josat.2023.209237_bb0265","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.addbeh.2011.01.032","article-title":"Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation","volume":"36","author":"Roman","year":"2011","journal-title":"Addictive Behaviors"},{"issue":"1","key":"10.1016\/j.josat.2023.209237_bb0270","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of US physicians trained to treat opioid use disorder","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"The Annals of Family Medicine"},{"issue":"10","key":"10.1016\/j.josat.2023.209237_bb0275","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.josat.2023.209237_bb0280","first-page":"276","article-title":"Drivers of excess costs of opioid abuse among a commercially insured population","volume":"23","author":"Scarpati","year":"2017","journal-title":"The American Journal of Managed Care"},{"issue":"6","key":"10.1016\/j.josat.2023.209237_bb0285","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11606-011-1962-8","article-title":"Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care","volume":"27","author":"Schackman","year":"2012","journal-title":"Journal of General Internal Medicine"},{"issue":"5","key":"10.1016\/j.josat.2023.209237_bb0290","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","article-title":"Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995\u20132009","volume":"103","author":"Schwartz","year":"2013","journal-title":"American Journal of Public Health"},{"issue":"3","key":"10.1016\/j.josat.2023.209237_bb0295","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/add.13622","article-title":"Patient-centered methadone treatment: A randomized clinical trial: Patient-centered methadone","volume":"112","author":"Schwartz","year":"2017","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.josat.2023.209237_bb0300","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1360-0443.2011.03700.x","article-title":"Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings: Methadone with v without counseling","volume":"107","author":"Schwartz","year":"2012","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.josat.2023.209237_bb0305","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.jsat.2004.09.006","article-title":"Pathways in the relapse\u2014Treatment\u2014Recovery cycle over 3 years","volume":"28","author":"Scott","year":"2005","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/j.josat.2023.209237_bb0310","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","article-title":"Update on barriers to pharmacotherapy for opioid use disorders","volume":"19","author":"Sharma","year":"2017","journal-title":"Current Psychiatry Reports"},{"key":"10.1016\/j.josat.2023.209237_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109343","article-title":"Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials","volume":"233","author":"Shulman","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.josat.2023.209237_bb0320","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00952990.2011.653426","article-title":"Opioid detoxification and naltrexone induction strategies: Recommendations for clinical practice","volume":"38","author":"Sigmon","year":"2012","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.josat.2023.209237_bb0325","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"j1550","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.josat.2023.209237_bb0330","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00004714-199602000-00010","article-title":"Buprenorphine versus methadone in the treatment of opioid dependence: Self-reports, urinalysis, and addiction severity index","volume":"16","author":"Strain","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.josat.2023.209237_bb0335","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.josat.2023.209237_bb0340","article-title":"Medicaid coverage of medication-assisted treatment for alcohol and opioid use disorders and of medication for the reversal of opioid overdose","author":"Substance Abuse and Mental Health Services Administration","year":"2018","journal-title":"Substance Abuse and Mental Health Services Administration."},{"key":"10.1016\/j.josat.2023.209237_bb0345","series-title":"Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on drug use and health","author":"Substance Abuse and Mental Health Services Administration","year":"2020"},{"key":"10.1016\/j.josat.2023.209237_bb0350","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.josat.2023.209237_bb0355","article-title":"TIP 63: Medications for opioid use disorder","author":"Substance Abuse and Mental Health Services Administration","year":"2021","journal-title":"Substance Abuse and Mental Health Services Administration."},{"key":"10.1016\/j.josat.2023.209237_bb0360","article-title":"Treatment episode data set (TEDS): 2020 admissions to and discharges from publicly funded substance use treatment facilities","author":"Substance Abuse and Mental Health Services Administration","year":"2022","journal-title":"Substance Abuse and Mental Health Services Administration."},{"key":"10.1016\/j.josat.2023.209237_bb0365","article-title":"Medications, counseling, and related conditions: Buprenorphine","author":"Substance Abuse and Mental Health Services Administration","year":"2023","journal-title":"Substance Abuse and Mental Health Services Administration."},{"key":"10.1016\/j.josat.2023.209237_bb0370","article-title":"Medications, counseling, and related conditions: Methadone","author":"Substance Abuse and Mental Health Services Administration","year":"2023","journal-title":"Substance Abuse and Mental Health Services Administration."},{"key":"10.1016\/j.josat.2023.209237_bb0375","unstructured":"Substance Abuse and Mental Health Services Administration. (2023c, January 25). Removal of DATA Waiver (X-Waiver) Requirement. Substance Abuse and Mental Health Services Administration. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/removal-data-waiver-requirement."},{"key":"10.1016\/j.josat.2023.209237_bb0380","series-title":"Use of medication-assisted treatment for opioid use disorders in employer-sponsored health insurance: Final report","author":"The Office of the Assistant Secretary for Planning and Evaluation","year":"2019"},{"key":"10.1016\/j.josat.2023.209237_bb0385","author":"The Pew Charitable Trusts"},{"issue":"5","key":"10.1016\/j.josat.2023.209237_bb0390","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","article-title":"Cost-effectiveness thresholds: The past, the present and the future","volume":"36","author":"Thokala","year":"2018","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.josat.2023.209237_bb0395","series-title":"Use of telemedicine while providing medication assisted treatment (MAT)","author":"U.S. Department of Health & Human Services","year":"2018"},{"key":"10.1016\/j.josat.2023.209237_bb0400","series-title":"FDA advisory committee meeting RBP-6000 briefing document","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.josat.2023.209237_bb0405","article-title":"Medicaid prescriptions for extended-release medications to treat opioid use disorder","author":"Urban Institute","year":"2020","journal-title":"Urban Institute."},{"issue":"1","key":"10.1016\/j.josat.2023.209237_bb0410","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13722-019-0166-0","article-title":"Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail","volume":"14","author":"Velasquez","year":"2019","journal-title":"Addiction Science & Clinical Practice"},{"issue":"2","key":"10.1016\/j.josat.2023.209237_bb0415","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: A review","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.josat.2023.209237_bb0420","doi-asserted-by":"crossref","first-page":"469","DOI":"10.18553\/jmcp.2005.11.6.469","article-title":"Direct costs of opioid Abuse in an insured population in the United States","volume":"11","author":"White","year":"2005","journal-title":"Journal of Managed Care Pharmacy"},{"issue":"4","key":"10.1016\/j.josat.2023.209237_bb0425","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/add.13219","article-title":"Measuring benefits of opioid misuse treatment for economic evaluation: Health related quality of life of opioid dependent individuals and their spouses as assessed by a sample of the US population","volume":"111","author":"Wittenberg","year":"2016","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.josat.2023.209237_bb0430","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","article-title":"Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis","volume":"160","author":"Yarborough","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.josat.2023.209237_bb0435","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1377\/hlthaff.2020.00611","article-title":"Medicaid physician fees remained substantially below fees paid by Medicare in 2019","volume":"40","author":"Zuckerman","year":"2021","journal-title":"Health Affairs (Project Hope)"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923002886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923002886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:51:40Z","timestamp":1757433100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875923002886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":86,"alternative-id":["S2949875923002886"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2023.209237","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2023.209237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"209237"}}